Cue Price To Sales Ratio vs Capex To Depreciation Analysis
CUE Stock | USD 1.14 0.04 3.64% |
Cue Biopharma financial indicator trend analysis is way more than just evaluating Cue Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cue Biopharma is a good investment. Please check the relationship between Cue Biopharma Price To Sales Ratio and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.
Price To Sales Ratio vs Capex To Depreciation
Price To Sales Ratio vs Capex To Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cue Biopharma Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have weak relationship.
The correlation between Cue Biopharma's Price To Sales Ratio and Capex To Depreciation is 0.31. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Cue Biopharma, assuming nothing else is changed. The correlation between historical values of Cue Biopharma's Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Cue Biopharma are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., Cue Biopharma's Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.
Correlation Coefficient | 0.31 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cue Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cue Biopharma sales, a figure that is much harder to manipulate than other Cue Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most indicators from Cue Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 24 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 45.9K | 928.2K | 2.7M | 2.8M | Net Interest Income | 45.9K | 214.4K | 1.4M | 1.5M |
Cue Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Cue Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cue Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 71.6M | 99.5M | 83.4M | 91.3M | 61.5M | 66.4M | |
Other Current Liab | 2.2M | (2.0M) | 333.6K | 3.6M | 4.1M | 4.3M | |
Total Current Liabilities | 11.7M | 16.3M | 12.8M | 11.5M | 17.1M | 10.1M | |
Total Stockholder Equity | 54.6M | 78.9M | 65.5M | 65.7M | 37.1M | 51.3M | |
Net Tangible Assets | 54.6M | 78.9M | 65.5M | 65.7M | 75.5M | 52.6M | |
Property Plant And Equipment Net | 7.2M | 8.9M | 11.9M | 10.7M | 7.1M | 6.4M | |
Net Debt | (38.5M) | (67.7M) | (54.3M) | (32.3M) | (33.8M) | (35.5M) | |
Retained Earnings | (108.5M) | (153.3M) | (197.4M) | (250.5M) | (301.2M) | (286.1M) | |
Accounts Payable | 882.7K | 2.1M | 2.6M | 2.7M | 3.5M | 1.9M | |
Cash | 44.3M | 74.9M | 64.4M | 51.6M | 48.5M | 47.6M | |
Non Current Assets Total | 10.6M | 12.0M | 14.9M | 14.1M | 10.1M | 8.6M | |
Non Currrent Assets Other | 3.4M | 3.0M | 2.9M | 3.2M | 2.8M | 2.1M | |
Other Assets | 3.4M | 3.1M | 3.0M | 3.4M | 3.9M | 2.1M | |
Cash And Short Term Investments | 44.3M | 84.9M | 64.4M | 76.3M | 48.5M | 54.1M | |
Common Stock Total Equity | 26.6K | 30.4K | 32.2K | 43.0K | 49.5K | 26.3K | |
Common Stock Shares Outstanding | 22.0M | 28.7M | 31.3M | 35.6M | 45.8M | 30.0M | |
Short Term Investments | 50.1K | 18.4M | 15.1M | 10.0M | 0.0 | 24.7M | |
Liabilities And Stockholders Equity | 71.6M | 99.5M | 83.4M | 91.3M | 61.5M | 66.4M | |
Non Current Liabilities Total | 5.4M | 4.3M | 5.1M | 14.1M | 7.4M | 5.1M | |
Other Current Assets | 860.1K | 2.5M | 1.8M | 1.7M | 1.2M | 1.2M | |
Other Stockholder Equity | 163.1M | 232.2M | 262.9M | 316.2M | 338.2M | 189.1M | |
Total Liab | 17.0M | 20.6M | 17.9M | 25.6M | 24.4M | 15.1M | |
Property Plant And Equipment Gross | 7.2M | 8.9M | 15.4M | 14.9M | 10.7M | 7.7M | |
Total Current Assets | 61.0M | 87.5M | 68.5M | 77.2M | 51.5M | 57.8M | |
Accumulated Other Comprehensive Income | (10.3K) | 7.1K | 0.0 | (95.9K) | (110.3K) | (115.8K) | |
Common Stock | 26.6K | 30.4K | 32.2K | 43.0K | 47K | 29.1K | |
Property Plant Equipment | 7.2M | 2.1M | 2.1M | 1.5M | 1.7M | 2.6M | |
Non Current Liabilities Other | 5.4M | 4.3M | 5.1M | 6.0M | 6.9M | 4.8M | |
Current Deferred Revenue | 4.1M | 6.7M | 645.3K | 2.1M | 2.4M | 3.0M | |
Net Invested Capital | 54.6M | 78.9M | 65.5M | 75.7M | 45.3M | 65.7M | |
Net Working Capital | 49.4M | 71.2M | 55.7M | 65.6M | 34.4M | 42.3M | |
Retained Earnings Total Equity | (108.5M) | (153.3M) | (197.4M) | (250.5M) | (225.4M) | (236.7M) | |
Capital Surpluse | 163.1M | 232.2M | 262.9M | 316.2M | 363.6M | 237.6M | |
Capital Stock | 26.6K | 30.4K | 32.2K | 43.0K | 47K | 36.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.